Nα-methyl-Nω-methyl-L-Arg

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Nα-methyl-Nω-methyl-L-Arg
• 英文别名: (2S)-2-(methylamino)-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid
• 化学式: C₈H₁₈N₄O₂
• 分子量: 202.257
• InChiKey: ANWIVFIUTDHNRX-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  99.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Boc-L-谷氨酰胺 在 platinum(IV) oxide 、 sodium hydroxide 、 水 、 氢气 、 乙酸酐 、 sodium hydride 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 为溶剂， 反应 220.0h， 生成 Nα-methyl-Nω-methyl-L-Arg
  参考文献：
  名称：

  Synthesis of cyclic and acyclic Nα-methyl-Nω-alkyl-l-arginine analogues

  摘要：

  A series of Nalpha-methyl-alkyl-L-arginine (Arg) analogues have been synthesized from inexpensive, commercially available starting rnaterials. These analogues, once incorporated into pharmaceutically relevant peptides, are expected to increase binding affinity, receptor selectivity, lipophificity, and stability Lis demonstrated With analogues of similar design and Structure. (C) 2001 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2004.01.047

文献信息

• Probes for In Vivo Targeting of Active Cysteine Proteases
  申请人：Bogyo Matthew S.

  公开号：US20090252677A1

  公开（公告）日：2009-10-08

  Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 64 Cu, 125 I (SPECT) and 99m Tc (PET). The probes show in vivo half-life and stability well suited for imaging.
• US7205384B2
  申请人：——

  公开号：US7205384B2

  公开（公告）日：2007-04-17
• US8343458B2
  申请人：——

  公开号：US8343458B2

  公开（公告）日：2013-01-01
• [EN] COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO CANCER SPECIFIC GENES AND PROTEINS<br/>[FR] COMPOSITIONS, VARIANTS D'EPISSAGE ET PROCEDES CONCERNANT DES GENES ET DES PROTEINES SPECIFIQUES DU CANCER
  申请人：DIADEXUS INC

  公开号：WO2004092338A2

  公开（公告）日：2004-10-28

  The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast, colon, lung, ovarian or prostate cancer and non-cancerous disease states in breast, colon, lung, ovarian or prostate, identifying breast, colon, lung, ovarian or prostate tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered normal or cancerous breast, colon, lung, ovarian or prostate tissue for treatment and research.
• [EN] COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO CANCER SPECIFIC GENES AND PROTEINS<br/>[FR] COMPOSITIONS, VARIANTS D'EPISSAGE ET METHODES RELATIFS AUX GENES ET AUX PROTEINES SPECIFIQUES DU CANCER
  申请人：DIADEXUS INC

  公开号：WO2007001399A2

  公开（公告）日：2007-01-04

  [EN] The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast, intestine and colon, lung, ovarian or prostate cancer and non-cancerous disease states in breast, intestine and colon, lung, ovarian or prostate, identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast, intestine and colon, lung, ovarian or prostate tissue for treatment and research.
  [FR] La présente invention concerne des molécules et des polypeptides de l'acide nucléique récemment identifiés et présents dans des cellules normales et néoplasiques comprenant des fragments, des variants et des dérivés des acides nucléiques et des polypeptides. L'invention concerne également des compositions contenant des molécules d'acide nucléique, des polypeptides, des agonistes et des antagonistes des polypeptides. L'invention concerne également des compositions contenant des molécules d'acide nucléique, des polypeptides, des anticorps, des agonistes et des antagonistes, et des méthodes d'utilisation de ces compositions. On utilise ces compositions dans l'identification, le diagnostic, la surveillance, la stadification, l'imagerie et le traitement du cancer du sein, des intestins et du colon, des poumons, des ovaires ou de la prostate et des états pathologiques non cancéreux affectant les seins, les intestins et le colon, les poumons, les ovaires ou la prostate. Ces compositions sont également utilisées dans l'identification et/ou la conception d'agonistes et d'antagonistes des polypeptides de l'invention. Ces compositions sont également utilisées dans la thérapie génique, la production d'animaux et de cellules transgéniques et dans la production de tissus génétiquement modifiés des organes tels que les seins, les intestins et le colon, les poumons, les ovaires ou la prostate et utilisés à des fins thérapeutiques et de recherche.